{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-24-000165","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.102325+00:00","generated_at":"2026-06-06T09:35:48.309476+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"IDEXX Q4 revenue $902M (+9%); FY24 guides $3.93-4.04B, EPS $10.84-11.33","bullets":["Q4 revenue $902M, up 9% reported and 8% organic; CAG Diagnostics recurring revenue +11% reported and +10% organic.","Q4 EPS $2.32, up 13% reported and 17% on a comparable basis; full-year EPS $10.06 (+25% reported).","FY24 revenue guidance $3.93B-$4.04B (+7.5%-10.5% reported); EPS $10.84-$11.33 (+8%-13% comparable).","Full-year operating margin expanded 330 bps reported; FY24 operating margin target 30.2%-30.7%.","New IDEXX inVue Dx slide-free cellular analyzer launch targeted for late 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-24-000165","json":"https://secwatch.observer/filing/0001157523-24-000165.json","markdown":"https://secwatch.observer/filing/0001157523-24-000165.md","text":"https://secwatch.observer/filing/0001157523-24-000165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000115752324000165/0001157523-24-000165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000115752324000165/a53891750.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:35:48.309476+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c3edbb9656ed8014b50040f43ed1da63d1f8fb14","claim":"IDEXX LABORATORIES INC /DE updated its the quarter and year ended December 31, 2023 guidance (initiated).","evidence_excerpt":"IDEXX Laboratories, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/874716/000115752324000165/0001157523-24-000165-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}